First PARP Inhibitor to Demonstrate Clinical Benefit in Radiographic Progression-Free Survival in Combination With New Hormonal Agent in This Setting
San Francisco, CA (UroToday.com) — AstraZeneca and Merck, known as MSD outside the United States and Canada, announced positive results from the Phase 3 PROpel trial, in which LYNPARZA in combination with abiraterone and prednisone demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone plus prednisone as a first-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.